|
Navigating the complexities in characterization of NDSRIs using advanced analytical techniques-Pub
|
|
2
|
255
|
March 12, 2026
|
|
Challenges in developing an analytical method for N‑nitroso‑ambroxol
|
|
3
|
243
|
March 11, 2026
|
|
Register for Free Webinar- Australia and New Zealand: Nitrosamines Impurities 19 March 2026
|
|
0
|
230
|
March 10, 2026
|
|
Register for Quality Hour- Japan Edition: Nitrosamines Impurities 18 March 2026
|
|
0
|
231
|
March 8, 2026
|
|
Nitrosamine analysis in suspension dosage forms
|
|
5
|
299
|
March 6, 2026
|
|
Nitrosamine Risk in Trospium chloride tablets
|
|
2
|
172
|
March 4, 2026
|
|
The Bench Mark dose (BMD) - Recorded full two day training FREE
|
|
4
|
403
|
March 4, 2026
|
|
Chat GPT's answer about the risk assessment of nitrosamine in pharmaceuticals
|
|
33
|
4015
|
February 28, 2026
|
|
Question about N-Nitroso nicardipine
|
|
5
|
866
|
February 28, 2026
|
|
N-Nitrosodibenzylamine infusion bags
|
|
0
|
126
|
February 27, 2026
|
|
Moxonidine Nitrosamines
|
|
6
|
295
|
February 25, 2026
|
|
Podcast: Reducing Nitrosamines and Driving Patient Safety
|
|
0
|
150
|
February 23, 2026
|
|
NDSRI growth with respect to age
|
|
11
|
463
|
February 23, 2026
|
|
Nitrosamine Risk Assessment on DETA
|
|
0
|
149
|
February 22, 2026
|
|
EMA proposes GMP update to EudraLex to address nitrosamine impurities
|
|
14
|
1158
|
February 20, 2026
|
|
Nitrites/Nitrosamines: The impacts on analytics, but not only
|
|
0
|
189
|
February 17, 2026
|
|
Calculation of Maximum Daily Dose (MDD) for 2 Strengths
|
|
5
|
339
|
February 17, 2026
|
|
Advantages and limitations of the inclusion of ascorbic acid on nitrosamine mitigation in pharmaceutical drug products-Pub
|
|
5
|
490
|
February 17, 2026
|
|
N-Nitroso methylphenidate anybody?
|
|
1
|
254
|
February 12, 2026
|
|
N-Nitroso Imidazole content in Clotrimazole
|
|
9
|
654
|
February 9, 2026
|
|
👨💻 Quantitation of N-Nitrosodimethylamine (NDMA) and N-Nitrosophenylephrine (NNPE) in Phenylephrine Hydrochloride (API) by LC-MS/MS
|
|
0
|
371
|
February 7, 2026
|
|
👨💻 N-Nitroso-Propranolol Test Method & Validation Report
|
|
0
|
180
|
February 7, 2026
|
|
👨💻 N-Nitroso-Methylphenidate Test Method and Validation Report
|
|
0
|
158
|
February 7, 2026
|
|
N-nitroso clonixin
|
|
3
|
159
|
February 6, 2026
|
|
Ames Concordance with the In Vivo Transgenic Rodent (TGR) Gene Mutation Assay for NDSRIs and Relative In Vivo TGR Potency with Nitrosamines with Robust Dose-Response Carcinogenicity Data-Pub
|
|
1
|
235
|
February 5, 2026
|
|
Available Tools for Prediction of Potential Degradation Products from Nitrosation Reactions
|
|
4
|
299
|
February 4, 2026
|
|
N-nitroso-rivaroxaban amide
|
|
7
|
2029
|
February 4, 2026
|
|
Nitrosamine control in Metformin /Vildagliptin DP
|
|
6
|
396
|
February 3, 2026
|
|
The role of pH, temperature and humidity in solid/liquid DP formulations
|
|
2
|
346
|
February 3, 2026
|
|
10th Impurities: Genotoxic, Nitrosamine, & Beyond Summit
|
|
2
|
402
|
February 2, 2026
|